Journal
BMC GASTROENTEROLOGY
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12876-023-02877-2
Keywords
Biomarker; Fibrosis; Compensated cirrhosis; Hepatic decompensation; Prognosis
Categories
Ask authors/readers for more resources
This study aimed to evaluate whether serum liver fibrosis markers can predict hepatic decompensation in patients with compensated cirrhosis. The results showed that serum LN and CIV levels were independently associated with hepatic decompensation. Particularly, CIV level appeared to be a reliable biomarker of disease progression and liver decompensation in patients with compensated cirrhosis.
Background and aimThe literature is sparse on the association between serum liver fibrosis markers and the development of hepatic decompensation in patients with compensated cirrhosis. We aimed to assessed whether the serum liver fibrosis markers are predictive of the occurrence of hepatic decompensation.MethodsWe ascertained 688 cirrhotic patients with varying etiologies, between December 2015 to December 2019. Serum hyaluronic acid (HA), laminin (LN), collagen IV (CIV), and N-terminal propeptide of type III collagen (PIIINP) levels were measured at enrollment. All subjects were followed for at least 6 months for occurrence of hepatic decompensation. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of hepatic decompensation during follow-up.ResultsDuring a median follow-up of 22.0 (13.0-32.0) months, decompensation occurred in 69 (10.0%) patients. Multivariate analysis indicated that higher LN (HR: 1.008, 95% confidence interval [CI]: 1.002-1.014, P = 0.011) and CIV (HR: 1.004, 95% CI: 1.001-1.007, P = 0.003) levels were independently associated with hepatic decompensation. Furthermore, patients in the tertile 2 and tertile 3 groups for CIV levels had HRs of 4.787 (1.419, 16.152) (P = 0.012) and 5.153 (1.508, 17.604) (P = 0.009), respectively, for occurrence of decompensation event compared with those in the tertile 1 group.ConclusionSerum liver fibrosis markers, particularly in CIV, appeared to be reliable biomarkers of disease progression and liver decompensation in patients with compensated cirrhosis with varying etiologies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available